Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 35

References for PMC Articles for PubMed (Select 17123821)

1.

Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.

Sedlacek H, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A, Sausville E.

Int J Oncol. 1996 Dec;9(6):1143-68.

PMID:
21541623
2.

Synthesis and anti-tubulin activity of a 3'-(4-azidophenyl)-3'-dephenylpaclitaxel photoaffinity probe.

Spletstoser JT, Flaherty PT, Himes RH, Georg GI.

J Med Chem. 2004 Dec 16;47(26):6459-65.

PMID:
15588080
3.

Toward a pharmacophore for kinase frequent hitters.

Aronov AM, Murcko MA.

J Med Chem. 2004 Nov 4;47(23):5616-9.

PMID:
15509160
4.

A new alkaloid from Dysoxylum binectariferum.

Yang DH, Cai SQ, Zhao YY, Liang H.

J Asian Nat Prod Res. 2004 Sep;6(3):233-6.

PMID:
15224423
5.

Protein kinase inhibitors: insights into drug design from structure.

Noble ME, Endicott JA, Johnson LN.

Science. 2004 Mar 19;303(5665):1800-5. Review.

PMID:
15031492
6.

Versatile fluorescence probes of protein kinase activity.

Shults MD, Imperiali B.

J Am Chem Soc. 2003 Nov 26;125(47):14248-9.

PMID:
14624552
7.

Novel small molecule cyclin-dependent kinases modulators in human clinical trials.

Senderowicz AM.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S84-95. Review.

8.

Cyclin-dependent kinase modulators studied at the NCI: pre-clinical and clinical studies.

Sausville EA.

Curr Med Chem Anticancer Agents. 2003 Jan;3(1):47-56. Review.

PMID:
12678914
9.

Kinase inhibitors: not just for kinases anymore.

McGovern SL, Shoichet BK.

J Med Chem. 2003 Apr 10;46(8):1478-83.

PMID:
12672248
10.

Issues and progress with protein kinase inhibitors for cancer treatment.

Dancey J, Sausville EA.

Nat Rev Drug Discov. 2003 Apr;2(4):296-313. Review.

PMID:
12669029
11.

Progress toward the development of agents to modulate the cell cycle.

Toogood PL.

Curr Opin Chem Biol. 2002 Aug;6(4):472-8. Review.

PMID:
12133723
12.

Protein kinases--the major drug targets of the twenty-first century?

Cohen P.

Nat Rev Drug Discov. 2002 Apr;1(4):309-15. Review.

PMID:
12120282
13.

Structure-based design and synthesis of 2-benzylidene-benzofuran-3-ones as flavopiridol mimics.

Schoepfer J, Fretz H, Chaudhuri B, Muller L, Seeber E, Meijer L, Lozach O, Vangrevelinghe E, Furet P.

J Med Chem. 2002 Apr 25;45(9):1741-7.

PMID:
11960485
14.

Cyclin-dependent kinases.

Harper JW, Adams PD.

Chem Rev. 2001 Aug;101(8):2511-26. Review. No abstract available.

PMID:
11749386
15.

Protein kinases as therapeutic targets.

Sridhar R, Hanson-Painton O, Cooper DR.

Pharm Res. 2000 Nov;17(11):1345-53. Review.

PMID:
11205726
16.

Flavopiridol, the first cyclin-dependent kinase inhibitor to enter the clinic: current status.

Kelland LR.

Expert Opin Investig Drugs. 2000 Dec;9(12):2903-11. Review.

PMID:
11093360
17.

Thio- and oxoflavopiridols, cyclin-dependent kinase 1-selective inhibitors: synthesis and biological effects.

Kim KS, Sack JS, Tokarski JS, Qian L, Chao ST, Leith L, Kelly YF, Misra RN, Hunt JT, Kimball SD, Humphreys WG, Wautlet BS, Mulheron JG, Webster KR.

J Med Chem. 2000 Nov 2;43(22):4126-34.

PMID:
11063609
18.

The therapeutic potential of flavonoids.

Wang HK.

Expert Opin Investig Drugs. 2000 Sep;9(9):2103-19. Review.

PMID:
11060796
19.

Cyclin-dependent kinase inhibitors: novel anticancer agents.

Mani S, Wang C, Wu K, Francis R, Pestell R.

Expert Opin Investig Drugs. 2000 Aug;9(8):1849-70. Review.

PMID:
11060782
20.

Inhibitors of cyclin-dependent kinases as anti-cancer therapeutics.

Fischer PM, Lane DP.

Curr Med Chem. 2000 Dec;7(12):1213-45.

PMID:
11032968
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk